$187 Million is the total value of MPM ASSET MANAGEMENT LLC's 7 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 12.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Entrada Therapeutics, Inc. | $69,927,387 | +4.4% | 4,425,784 | 0.0% | 37.45% | +14.0% | ||
DYN | Dyne Therapeutics, Inc. | $44,363,675 | -20.4% | 4,951,303 | 0.0% | 23.76% | -13.0% | |
ITOS | iTeos Therapeutics, Inc. | $29,989,696 | -17.3% | 2,738,785 | 0.0% | 16.06% | -9.7% | |
RPTX | Repare Therapeutics, Inc. | $27,091,043 | +14.2% | 2,242,636 | 0.0% | 14.51% | +24.7% | |
HOWL | Werewolf Therapeutics, Inc. | $9,168,128 | -29.8% | 4,284,172 | 0.0% | 4.91% | -23.4% | |
ADAP | Adaptimmune Therapeutics plcsponsored adr | $4,903,939 | -15.7% | 6,287,101 | 0.0% | 2.63% | -7.9% | |
HARP | Sell | Harpoon Therapeutics, Inc. | $1,261,938 | -43.2% | 313,136 | -90.0% | 0.68% | -38.0% |
ONCR | Exit | Oncorus, Inc. | $0 | – | -2,849,464 | -100.0% | -0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Chiasma, Inc. | 24 | Q2 2021 | 19.8% |
Aratana Therapeutics, Inc. | 24 | Q1 2019 | 26.8% |
Conatus Pharmaceuticals, Inc. | 23 | Q1 2019 | 9.7% |
Rhythm Pharmaceuticals, Inc. | 19 | Q2 2022 | 69.9% |
Harpoon Therapeutics, Inc. | 19 | Q3 2023 | 31.9% |
Syndax Pharmaceuticals, Inc. | 19 | Q3 2020 | 14.5% |
Radius Health, Inc. | 17 | Q2 2018 | 76.4% |
TCR2 Therapeutics, Inc. | 17 | Q1 2023 | 29.1% |
Proteon Therapeutics, Inc. | 17 | Q4 2018 | 3.0% |
EpiZyme, Inc. | 15 | Q4 2016 | 35.9% |
View MPM ASSET MANAGEMENT LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR/A | 2023-09-07 |
13F-HR | 2023-08-14 |
4 | 2023-06-05 |
4 | 2023-05-24 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-11 |
View MPM ASSET MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.